Whilst breast cancers arising in patients with BRCA1 or BRCA2 mutation carriers account for less than 5% of breast cancers, if epigenetic alterations, such as BRCA1 methylation are taken into account these make up approximately 15% of all patients and almost half of those with TNBC. This evidence concerns the gene BRCA2 and breast carcinoma.